YAP Regulates PD-L1 Expression in Human NSCLC Cells
Overview
Authors
Affiliations
Programmed death-ligand 1 (PD-L1) is a membrane protein on tumor cells that binds to the PD-1 receptor expressed on immune cells, leading to the immune escape of tumor cells. Yes-associated protein (YAP) is a main effector of the Hippo/YAP signaling pathway, which plays important roles in cancer development. Here we show that YAP regulates PD-L1 expression in human non-small cell lung cancer (NSCLC) cells. First, we investigated YAP and PD-L1 expression at the protein level in 142 NSCLC samples and 15 normal lung samples. In tumor tissue, immunohistochemistry showed positive staining for YAP and PD-L1, which correlated significantly ( = 142, = 0.514, < 0.001). Second, in cell lines that express high levels of PD-L1 (H460, SKLU-1, and H1299), the ratio of p-YAP/YAP was lower and GTIIC reporter activity of the Hippo pathway was higher than those in three cell lines expressing low levels of PD-L1 (A549, H2030, and PC9) ( < 0.05). Third, in the same three cell lines, inhibition of YAP by two small interfering RNAs (siRNAs) decreased the mRNA and protein level of PD-L1 ( < 0.05). Fourth, forced overexpression of the YAP gene rescued the PD-L1 mRNA and protein level after siRNA knockdown targeting 3'UTR of the endogenous YAP gene. Finally, chromatin immunoprecipitation (ChIP) assays using a YAP-specific monoclonal antibody resulted in the precipitation of PD-L1 enhancer region encompassing two putative TEAD binding sites. Our results indicate that YAP regulates the transcription of PD-L1 in NSCLC.
Zhu Z, Ding R, Yu W, Liu Y, Zhou Z, Liu C Cell Death Differ. 2025; .
PMID: 39875519 DOI: 10.1038/s41418-025-01446-2.
Transient activation of YAP/TAZ confers resistance to morusin-induced apoptosis.
Lee H, Cho S, Cha H, Tae K, Choi C BMC Mol Cell Biol. 2025; 26(1):4.
PMID: 39833669 PMC: 11744988. DOI: 10.1186/s12860-025-00531-1.
Pan-cancer analysis of the prognostic and immunological role of hippo-YAP signaling pathway.
Yang J, Yang C, Yang G, Wang R, Li J, Song Y Discov Oncol. 2024; 15(1):504.
PMID: 39333438 PMC: 11436565. DOI: 10.1007/s12672-024-01212-9.
Targeted degradation of specific TEAD paralogs by small molecule degraders.
Chen H, Gridnev A, Schlamowitz N, Hu W, Dey K, Zheng G Heliyon. 2024; 10(18):e37829.
PMID: 39328531 PMC: 11425103. DOI: 10.1016/j.heliyon.2024.e37829.
Targeting the Hippo pathway to prevent radioresistance brain metastases from the lung (Review).
Taylor J, Dubois F, Bergot E, Levallet G Int J Oncol. 2024; 65(1).
PMID: 38785155 PMC: 11155713. DOI: 10.3892/ijo.2024.5656.